FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

The FDA has approved Lisraya (brepocitinib), the first oral drug for treating dermatomyositis in adults, providing a new effective treatment option for this rare autoimmune disease. This approval follows a successful phase 3 clinical trial demonstrating significant improvement in patients’ symptoms and disease control.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.